Trinity Biotech

Trinity Biotech Inventory/Revenue

The Inventory to Revenue Ratio of Trinity Biotech (TRIB) as of Nov 10, 2026 is 43.00 %. In the previous year, Inventory to Revenue Ratio was 31.47 % — a change of 36.62% (higher).

Inventory/Revenue

43.00 %

YoY

36.62%

Last updated:

Inventory to Revenue Ratio of Trinity Biotech is 2025 43.00 % . Inventory to Revenue Ratio of Trinity Biotech was 2024 31.47 % . It decreases by 36.62% higher compared to the previous year.

The Trinity Biotech Inventory/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory/Revenue
Date
Inventory/Revenue
Jan 1, 2018
31.29 USD
Jan 1, 2019
35.41 USD
Jan 1, 2020
29.63 USD
Jan 1, 2021
35.89 USD
Jan 1, 2022
35.99 USD
Jan 1, 2023
35.07 USD
Jan 1, 2024
31.47 USD
Jan 1, 2025
43.00 USD
The Trinity Biotech Inventory/Revenue history
YEARInventory/RevenueYoY
43.00 %+36.62%
31.47 %-10.26%
35.07 %-2.55%
35.99 %+0.29%
35.89 %+21.11%
29.63 %-16.31%
35.41 %+13.17%
31.29 %-5.45%
33.09 %+1.14%
32.72 %-6.68%
35.06 %+9.69%
31.96 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Inventory to Revenue Ratio of Trinity Biotech is 43.00 % in 2025.

Inventory to Revenue Ratio of Trinity Biotech changed from 31.47 % to 43.00 %, representing a 36.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory to Revenue Ratio Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

The Inventory/Revenue ratio shows what percentage of revenue is held as inventory. Rising ratios may indicate slowing demand or inventory management issues.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Inventory to Revenue Ratio's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Inventory to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Inventory to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Trinity Biotech

All Key Metrics — Trinity Biotech